In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment till disorder progression or maybe the members are not able to tolerate the study drugs. In general, our recent work highlights the potential utilization of ARV-825 in https://landendpzkv.angelinsblog.com/31404713/clinical-trial-recruitment-for-abbv-744-study-fundamentals-explained